Abstract
Suppression of cell death (most often apoptosis) by survival signals, or by defects in cell death signal transduction pathways, is considered one of the obligate hallmarks of malignant transformation. However, molecular survival strategies to evade cell death only have relevance in the presence of pro-death signals. Discovery of the apoptotic properties of oncogenes responsible for increased tumor cell proliferation (e.g. c-Myc) provided the most important example for such signals and led to the concept of synthetic lethal targeting as a strategy of identifying cancer specific drug target molecules. Besides growth signal autonomy, other hallmarks of oncogenesis (insensitivity to anti-growth signals, limitless replicative potential, invasion and metastasis, angiogenesis and increased genomic instability) are also challenged by increased susceptibility to various forms of cell death. Therefore, cancer cells must acquire survival strategies to suppress these cell death/apoptosis mechanisms. Novel signal transduction therapies can target molecules involved in these strategies to trigger tumor specific cell death.
Keywords: Cell death, apoptosis, cancer
Current Signal Transduction Therapy
Title: Molecular Targeting of Cell Death Signal Transduction Pathways in Cancer
Volume: 1 Issue: 1
Author(s): Istvan Petak, Janet A. Houghton and Laszlo Kopper
Affiliation:
Keywords: Cell death, apoptosis, cancer
Abstract: Suppression of cell death (most often apoptosis) by survival signals, or by defects in cell death signal transduction pathways, is considered one of the obligate hallmarks of malignant transformation. However, molecular survival strategies to evade cell death only have relevance in the presence of pro-death signals. Discovery of the apoptotic properties of oncogenes responsible for increased tumor cell proliferation (e.g. c-Myc) provided the most important example for such signals and led to the concept of synthetic lethal targeting as a strategy of identifying cancer specific drug target molecules. Besides growth signal autonomy, other hallmarks of oncogenesis (insensitivity to anti-growth signals, limitless replicative potential, invasion and metastasis, angiogenesis and increased genomic instability) are also challenged by increased susceptibility to various forms of cell death. Therefore, cancer cells must acquire survival strategies to suppress these cell death/apoptosis mechanisms. Novel signal transduction therapies can target molecules involved in these strategies to trigger tumor specific cell death.
Export Options
About this article
Cite this article as:
Petak Istvan, Houghton A. Janet and Kopper Laszlo, Molecular Targeting of Cell Death Signal Transduction Pathways in Cancer, Current Signal Transduction Therapy 2006; 1 (1) . https://dx.doi.org/10.2174/157436206775269217
DOI https://dx.doi.org/10.2174/157436206775269217 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of PET/CT and SPECT/CT in Oncology Drug Development
Current Molecular Imaging (Discontinued) In Vivo Tumor Secretion Probing Via Ultrafiltration and Tissue Chamber:Implication for Anti-Cancer Drugs Targeting Secretome
Recent Patents on Anti-Cancer Drug Discovery Therapeutic Potential of Group III Metabotropic Glutamate Receptors
Current Medicinal Chemistry DNA Demethylation by TET Proteins: A Potential Therapeutic Target in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) In Vitro Modeling of the Blood-Brain Barrier: Simplicity Versus Complexity
Current Pharmaceutical Design Recent Advances in Application of Poly-Epsilon-Caprolactone and its Derivative Copolymers for Controlled Release of Anti-Tumor Drugs
Current Cancer Drug Targets Strategies to Overcome or Circumvent P-Glycoprotein Mediated Multidrug Resistance
Current Medicinal Chemistry Mitochondria as Possible Pharmaceutical Targets for the Effects of Vitamin E and its Homologues in Oxidative Stress-Related Diseases
Current Pharmaceutical Design Death Receptor Signaling in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Stimulation of Peroxisome Proliferator-Activated Receptor-Gamma (PPARγ) using Pioglitazone Decreases the Survival of Acute Promyelocytic Leukemia Cells through Up-Regulation of PTEN Expression
Anti-Cancer Agents in Medicinal Chemistry Poly (ADP-Ribosyl) Polymerase 1 Inhibitors: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery Selective Modulator of Cannabinoid Receptor Type 2 Reduces Memory Impairment and Infarct Size During Cerebral Hypoperfusion and Vascular Dementia
Current Neurovascular Research Saponins in Tumor Therapy
Mini-Reviews in Medicinal Chemistry The Role of Brain Cholesterol and its Oxidized Products in Alzheimer's Disease
Current Alzheimer Research Biological Activities of QIAPI 1 as a Melanin Precursor and Its Therapeutic Effects in Wistar Rats Exposed to Arsenic Poisoning
Central Nervous System Agents in Medicinal Chemistry Targeted Toxins for Glioblastoma Multiforme: Pre-Clinical Studies and Clinical Implementation
Anti-Cancer Agents in Medicinal Chemistry Cancer Stem Cells: How can we Target them?
Current Medicinal Chemistry Identification of Novel Drug Targets for Angiostatic Cancer Therapy; It Takes Two to Tango
Current Pharmaceutical Design The Tumor Stroma as Mediator of Drug Resistance - A Potential Target to Improve Cancer Therapy?
Current Pharmaceutical Biotechnology Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
Current Drug Targets